期刊
EXPERT OPINION ON BIOLOGICAL THERAPY
卷 18, 期 8, 页码 911-920出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/14712598.2018.1494719
关键词
Belimumab; biological agents; drug efficacy; rheumatology; systemic lupus erythematosus
资金
- Swedish Research Council
- King Gustaf V's 80-year Foundation
- Swedish Society of Medicine
- Professor Nanna Svartz Foundation
- Swedish Heart-Lung Foundation
- Foundation in memory of Clas Groschinsky
- King Gustaf V and Queen Victoria's Foundation of Freemasons
- Region Ostergotland
- Stockholm County Council
- Karolinska Institutet Foundations
- Lund University Medical Faculty Foundation
- Alfred Osterlund's Foundation
- Anna-Greta Crafoord Foundation
- Greta and Johan Kock's Foundation
- Lund University Hospital
- Swedish Rheumatism Association
Objectives: Recently, we demonstrated a negative impact of smoking on belimumab efficacy in patients with systemic lupus erythematosus (SLE). Here, we particularly investigated clinical effects of belimumab and a potential impact of smoking in mucocutaneous and articular SLE. Methods: We surveyed 62 SLE patients treated between 2011 and 2017. Evaluation included the mucocutaneous descriptors of SLEDAI-2K (rash, alopecia, mucosal ulcers; mcSLEDAI-2K), CLASI, the arthritis SLEDAI-2K descriptor (arSLEDAI-2K) and the 28-joint count. Results: mcSLEDAI-2K and CLASI activity decreased from baseline to month 6 and 12 (P < 0.001 for all). No worsening in CLASI damage was observed. Current or previous smokers displayed a higher probability of unchanged/worsened mcSLEDAI-2K compared to never smokers (OR: 6.4; 95% CI: 1.5-27.4; P = 0.012), also after adjustment for antimalarial agents. arSLEDAI-2K scores had decreased at month 6 (P < 0.001) and 12 (P < 0.001). Likewise, tender and swollen 28-joint counts had improved at month 6 (P = 0.010 and P < 0.001, respectively) and 12 (P = 0.001 for both). We observed no impact of smoking on belimumab efficacy in articular SLE. Conclusion: We observed a negative impact of smoking on the efficacy of belimumab in mucocutaneous SLE. In contrast, no impact of smoking on belimumab efficacy was seen in patients with articular manifestations.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据